128 results on '"Marsh J"'
Search Results
2. Characteristics and outcomes of aplastic anemia in HIV patients: a brief report from the severe aplastic anemia working party of the European Society of Blood and Bone Marrow Transplantation
3. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
4. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation
5. RETROSPECTIVE COMPARISON OF HPC-A COLLECTION EFFICIENCY BETWEEN SPECTRA OPTIA® AND COBE SPECTRA® CELL SEPARATORS IN A LARGE TERTIARY COLLECTION FACILITY.: PH-AB200
6. EBV REACTIVATION AND PTLD IN PATIENTS RECEIVING HSCT FOR APLASTIC ANAEMIA: PH-AB075
7. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS FEASIBLE AFTER SOLID ORGAN TRANSPLANTATION: FINAL ANALYSIS BY THE EARLY COMPLICATIONS SUBCOMMITTEE OF THE COMPLICATIONS AND QUALITY OF LIFE WORKING PARTY, EBMT: PH-P351
8. PREDICTING FACTORS FOR INPATIENT MORTALITY AND LONG TERM SURVIVAL IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO INTENSIVE CARE UNIT: PH-P317
9. HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IS A THERAPEUTIC OPTION IN PATIENTS WITH REFRACTORY ACQUIRED SEVERE APLASTIC ANEMIA: A SURVEY BY THE SEVERE APLASTIC ANEMIA WORKING PARTY (SAAWP) AND PAEDIATRIC DISEASES WORKING PARTY (PDWP) OF THE EU: WP-O007
10. THE RACE STUDY: A SAAWP PROSPECTIVE RANDOMIZED MULTICENTER STUDY COMPARING HORSE ANTITHYMOCYTE GLOBULIN (HATG) + CYCLOSPORINE A (CSA) WITH OR WITHOUT ELTROMBOPAG AS FRONT-LINE THERAPY FOR SEVERE APLASTIC ANAEMIA PATIENTS: WP-O005
11. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation
12. Hematopoietic SCT in Europe: data and trends in 2011
13. Unrelated donor HSCT for acquired severe aplastic anaemia: report from the EBMT Severe Aplastic Anaemia Working Party: 116
14. Treatment of aplastic anaemia with Antithymocyte globulin (ATG): current situation regarding horse vs rabbit ATG; a report from the EBMT Severe Aplastic Anaemia Working Party: 117
15. Treatment of aplastic anaemia in elderly patients aged > 60 years
16. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression
17. The EBMT activity survey: 1990-2010
18. Retrospective analysis of 5-azacitidine as induction therapy prior to haematopoietic stem cell transplantation: P1172
19. Outcomes and risk factors of matched donor transplantation for Fanconi anaemia: a retrospective study for the Severe Aplastic Anaemia Working Party (SAA-WP): 207
20. Prospective phase II pilot study of rabbit antithymocyte globulin (ATG, Thymoglobuline) with ciclosporin for patients with acquired aplastic anaemia and matched pair analysis with patients treated with horse ATG and ciclosporin: 208
21. Outcome of aplastic anaemia in adolescents: a retrospective analysis from the SAAWP of the EBMT: 209
22. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience
23. Survival of patients with documented autologous recovery after SCT for severe aplastic anemia: a study by the WPSAA of the EBMT
24. Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia
25. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML
26. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia
27. Does using a new donor for second haematopoietic stem cell transplantation for patients with Fanconi anaemia influence the outcome? A survey from the EBMT Severe Aplastic Anaemia Working Party: 317
28. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the EBMT Severe Aplastic Anaemia Working Party: 315
29. An unusual cause of acute abdomen following allogeneic transplantation: a zoonotic disease revisited
30. Subcutaneous alemtuzumab is safe and effective for treatment of global or single-lineage immune-mediated marrow failure: a pilot study from the Working Party Aplastic Anaemia (WPSAA)
31. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia
32. Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan
33. Marrow transplantation for severe aplastic anemia with significant renal impairment
34. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia
35. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party
36. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning
37. In vivo anti-CD52 monoclonal antibodies in bone marrow transplantation for acquired aplastic anaemia
38. Treatment of aplastic anaemia in elderly patients aged >60 years
39. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression
40. Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia
41. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML
42. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia
43. Allogeneic peripheral blood stem cell transplantation for haematological malignancies – an analysis of kinetics of engraftment and GVHD risk
44. Treatment of aplastic anaemia in elderly patients aged >60 years.
45. Liver function abnormality following treatment with antithymocyte globulin for aplastic anaemia.
46. Correction to: Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP of EBMT).
47. Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT).
48. Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT).
49. Hyperhydration is not necessary for high-dose melphalan in stem cell transplantation.
50. Allogeneic stem cell transplantation for Fanconi Anaemia. Severe Aplastic Anaemia Working Party of the EBMT and EUFAR. European Group for Blood and Marrow Transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.